Does extending hormonal therapy impact risk of breast cancer recurrence?
Full article:

Hormonal therapy significantly reduces the risk of recurrence for women with early-stage estrogen receptor-positive breast cancer. Standard hormonal therapy is given for 5 years; extending that therapy for a longer period offers additional protection but has added side effects. This study looked at women who stopped hormonal therapy after 5 years and identified factors that may guide the decision to extend treatment.  (12/21/17)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies enrolling people with early stage ER-positive, HER2-negative breast cancer. 

A number of other clinical trials for patients with early-stage breast cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.